Dust entry
Airborne particulate from soluble thallium compounds. The cited NIOSH profile identifies skin absorption and systemic toxicity; hazard details vary by compound.
The form describes what is suspended in air at the point of exposure. A material can produce more than one form, such as dust during handling and fume during heating.
NIOSH lists a 0.1 mg/m³ TWA REL with a skin designation and a 15 mg/m³ IDLH for soluble thallium compounds.
IDLH 15 mg/m³ (as Tl). NIOSH REL TWA 0.1 mg/m³ [skin]. OSHA PEL TWA 0.1 mg/m³ [skin].
NIOSH reports inhalation, skin absorption, ingestion, and skin and/or eye contact as exposure routes and identifies respiratory, central nervous system, liver, kidney, gastrointestinal, eye, and hair effects among the hazard profile.
Exposure Routes inhalation, skin absorption, ingestion, skin and/or eye contact. Symptoms nausea, diarrhea, abdominal pain, vomiting; ptosis, strabismus; peri neuritis, tremor; retrosternal tightness, chest pain, pulmonary edema; convulsions, chorea, psychosis; liver, kidney damage; alopecia; paresthesia legs. Target Organs Eyes, respiratory system, central nervous system, liver, kidneys, gastrointestinal tract, body hair.
NIOSH reports a revised IDLH of 15 mg Tl/m³ and states that no inhalation toxicity data were available on which to base it for soluble thallium compounds; the basis includes acute oral toxicity data.
Human data: Lethal oral doses ranging from 0.9 to 9.4 mg/kg have been reported. Revised IDLH: 15 mg Tl/m³. Basis for revised IDLH: No inhalation toxicity data are available on which to base an IDLH for soluble thallium compounds.
NIOSH states that thallium is not classifiable as a carcinogen and is not suspected to be a carcinogen in its emergency-response profile.
Thallium is not classifiable as a carcinogen, and it is not suspected to be a carcinogen.